1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFY27 GLIA-CTN Advocacy Advancement Award is sponsored by Rare Diseases Clinical Research Network (RDCRN). This award supports registered 501(c)(3) nonprofit organizations focused on promoting awareness, research, and/or fundraising for leukodystrophy research. The award criteria are deliberately broad to accommodate diverse and evolving needs of individual leukodystrophy communities.
Get alerted about grants like this
Save a search for “Rare Diseases Clinical Research Network (RDCRN)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Career Development Award | Global Leukodystrophy Initiative Clinical Trials Network An NIH-Funded Rare Diseases Clinical Research Network Consortium FY27 GLIA-CTN Career Development Award The GLIA-CTN Career Development Award is a mentored award designed to provide "protected time" for clinically trained individuals to receive supervised training in biomedical research related to leukodystrophies.
A long-term goal is to establish a Leukodystrophy Center at each award recipient’s local institution. The award supports a period of supervised research, in conjunction with career development opportunities, for physician-scientists who require additional mentored training and support during development of an innovative research project. A full-length copy of the RFA is available here .
Applications must be received no later than February 28, 2026 (11:59PM EST) . One GLIA-CTN Career Development Award will be awarded in FY27 with a start date no later than September 1, 2026. Support will be provided for a one-year period.
The GLIA-CTN Career Development Award will provide up to $85,000 for research and salary, inclusive of appropriate fringe and indirect costs. We recommend that the applicant ask for a waiver of indirect costs. No greater than 8% indirect costs are permitted.
Candidates for the award must have a doctoral degree within the health professions (e.g., MD, DO, DDS, DMD, OD, DC, PharmD) and be actively affiliated with a US-based academic and/or health care institution. Individuals with degrees in nursing research and/or practice, who are licensed to practice clinically, may be eligible. There are also certain circumstances in which individuals with a PhD may be eligible, outlined below.
Innovative, early-stage applications addressing key knowledge gaps that are without evidence of alternate means of funding (i.e., “high-risk/high-yield”) are encouraged. Eligible applications will meet the following key criteria. The application must relate to a specific established leukodystrophy ( see Vanderver et al.
, Mol Genet Metab. 2015; doi: 10. 1016/j.
ymgme. 2015. 01.
006 ); The application should include a preliminary feasibility assessment for the creation of a leukodystrophy center at the applicant’s institution.
Preference will be given to applications that include an institutional letter of support to provide matching funding and resource allocation for the creation of such a center, including clinical care, diagnostic, and research resources that address the unique needs of patients with inherited white matter diseases; The applicant must have adequate training to care for patients with leukodystrophy; The application must include a pathway to additional funding or a subsequent career development award; Although applicants must identify mentorship within the GLIA-CTN, co-mentorship beyond the GLIA-CTN will be permitted if appropriate to the scientific goals and academic development of the applicant; The applicant must demonstrate willingness to collaborate with the GLIA-CTN in a sustainable way, including adoption of centralized/standardized data collection tools managed by the GLIA-CTN Biomedical Informatics and Statistical Core (BISC); The applicant must be within five years of completion of last training (i.e., last clinical or research fellowship); Applicants holding a PhD only must demonstrate integration with the clinical team at their site, as well as partnership with clinicians to facilitate the establishment of a local Leukodystrophy Center.
The applicant must describe scientific methods that demonstrate adequate rigor and replication to translate the proposed research project into future clinical studies (i.e., description of alternative approaches or “Go/No-Go” criteria). Applications should also meet the following feasibility criteria.
The applicant must demonstrate approval by their local Institutional Review Board (IRB) and, if appropriate, their Institutional Animal Care and Use Committees (IACUC) prior to accepting award funding. For pilot projects involving interventional approaches, the application must include a protocol synopsis and evidence of submission to appropriate regulatory bodies prior to submission.
At this time, only US-based investigators are eligible to apply for funding through a GLIA-CTN Career Development Award. We hope to be able to include international applicants in future award cycles.
In the meantime, alternative funding mechanisms may be available to support international researchers interested in proposing either a new pilot project or collaborating on an existing project within one of the key disease areas outlined in Appendix A of the Request for Applications (RFA), available for download here. Please contact GLIA-CTN Administrative Director, Omar Sherbini, MPH, at email@theglia.
org or 215-590-3068 for additional details. Successful applications will include an institutional letter of support outlining matching funding and resource allocation for the creation of a Leukodystrophy Center. Please see Eligibility Criteria for details.
Applications that include a plan to leverage central GLIA-CTN resources in one or more of the following ways will be prioritized: Use of existing phenotype and longitudinal natural history previously collected through the consortium’s central repository, known as the Myelin Disorders Biorepository Project (MDBP); Use of banked and/or prospectively collected biospecimen obtained by one or more clinical research centers currently participating in the GLIA-CTN; Inclusion of one or more GLIA-CTN Principal and/or Site Investigators in project design and/or execution; Inclusion of one or more GLIA-CTN Advocacy Committee Members/Organizations in project design and/or execution.
Standard reporting requirements include the following.
A progress report will be expected at six (6) months following award, and a final report will be expected at twelve (12) months following award; Funds will be disbursed within thirty (30) days of the project start date; Publication in the form of an abstract at a national or international meeting or submission of a manuscript for publication is expected within twelve (12) months of completion of the award; Standard reporting requirements include the following.
A progress report will be expected at six (6) months following award, and a final report will be expected at twelve (12) months following award; Funds will be disbursed within thirty (30) days of the project start date; Publication in the form of an abstract at a national or international meeting or submission of a manuscript for publication is expected within twelve (12) months of completion of the award; The awardee is expected to attend, and be prepared to discuss their career development project, at the GLIA-CTN Annual Instigator Meeting (Summer 2026), and attend the next GLIA Scientific Meeting (Spring 2027) after completion of their award.
Data Sharing Requirements IRB/IACUC protocols must include language that permits Protected Health Information (PHI) to be shared with the Children’s Hospital of Philadelphia (CHOP), and with the Rare Diseases Clinical Research Network (RDCRN) Data Management and Coordinating Center (DMCC) designated by the National Institutes of Health.
Suggested Application Structure The GLIA-CTN Career Development Committee recommends the following application structure.
Pilot Proposal (2-3 Pages): Background, Innovation, Approach (inc. Specific Aims, Preliminary Data and Methods), Project Timeline, and Future Directions; Career and Program Development (2 Pages) : Candidate Background and Goals, Training Objectives, GLIA-CTN Mentor, Coursework and Seminars, Leukodystrophy Program Development, Program Structure, and Future Development; *In standard NIH format per https://grants. nih.
gov/grants/forms/biosketch. htm . The following criteria will be considered during the review process.
Does the application meet the eligibility requirements? Have efforts been made to connect with leaders in advocacy organization(s) related to the disease(s) of focus in the application, or is there a clearly outlined plan to do so? Are the aims well defined?
Is the approach innovative? Are the methods appropriate? Will the collected data answer the stated aims?
Is the budget adequate and the timeline realistic? Is there strong institutional support for creation of a local Leukodystrophy Center? All applications will undergo the following two-stage process.
Applicants will submit a first-round application for review by the GLIA-CTN Career Development Committee. Feedback will be provided to all applicants. Applicants with strong proposals will be invited to incorporate the Committee’s feedback and submit a revised application for a second round of review.
Disorders/Topics of Interest Proposals focused on leukodystrophies listed in Appendix A of the RFA will be given priority. Please click here for access to the full RFA. Applicants interested in other conditions should contact the GLIA-CTN Career Development Committee before submitting a new application.
Questions regarding the application requirements, submission guidelines, etc. may be directed to GLIA-CTN Administrative Director, Omar Sherbini, MPH, at email@theglia. org or or 215-590-3068.
According to the current listing, eligibility includes: Any registered 501(c)(3) nonprofit organization focused on promoting awareness, research, and/or fundraising for leukodystrophy research is eligible to apply. Confirm the full requirements in the official notice before applying.
FY27 GLIA-CTN Advocacy Advancement Award is funded by Rare Diseases Clinical Research Network (RDCRN). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
FY27 GLIA-CTN Career Development Award is sponsored by Rare Diseases Clinical Research Network (RDCRN) - GLIA-CTN. This is a mentored award designed to provide protected time for clinically trained individuals to receive supervised training in biomedical research related to leukodystrophies. Argininosuccinic aciduria can have neurological implications, and gene therapy research that touches on neurological aspects or underlying metabolic pathways relevant to leukodystrophies could be a fit.
Rare Disease Pilot Grants and Other Requests for Applications (ARISEN Pilot Research Grant) is sponsored by Rare Diseases Clinical Research Network (RDCRN) - Autoimmunity, Rasmussen's, Inflammation & Status Epilepticus research Network (ARISEN). The ARISEN network invites applications for pilot research projects that accelerate clinical research in rare diseases aligned with the consortium's mission. While focused on autoimmune encephalitis, Rasmussen syndrome, and NORSE/FIRES, research into related rare diseases with similar underlying mechanisms might be considered.
BDCRC Early Career Investigator Grant is sponsored by Rare Diseases Clinical Research Network (RDCRN). The Early Career Investigator Grants (ECIG) address training needs in rare disease research by providing specialized education in the complexities of clinical research in the neuronal ceroid lipofuscinoses (NCLs). While primarily focused on NCLs, the general aim of supporting early career investigators in rare disease research could potentially be relevant if the proposed research also contributes to the broader understanding of rare autoimmune conditions.
On June 2, 2026, the Department of Energy's Office of Critical Minerals and Energy Innovation selected two demonstration-scale facilities — Phoenix Tailings (with MIT and the University of Minnesota) for $66 million, and the Colorado School of Mines (with ElementUSA, PNNL, Principal Mineral, and Rare Earth Technologies Inc.) for the balance — under the Rare Earth Elements Demonstration Facility Program. Both projects pull rare earths from industrial waste — red mud at the Gramercy refinery in Louisiana, and a mix of mine and refining tailings elsewhere. Here is what the selections tell researchers, small businesses, and downstream magnet customers about where DOE thinks the chokepoint actually is, and what to do before the next demonstration-scale solicitation opens.
Read articlePAR-26-042 funds NLM-priority clinical informatics R01 grants up to $250,000 in direct costs per year through March 6, 2029, with standard NIH cycles on October 5, February 5, and June 5. The notice explicitly defines non-responsive applications: incremental tool improvements, projects primarily focused on social determinants of health, and projects primarily focused on ethical/legal/social issues. With NIH SBIR/STTR just reopened and the OMB Uniform Grants Regulation rewrite reshaping discretionary awards, the NLM clinical informatics line is one of the few stable, well-defined biomedical funding streams left at the agency. Here is how to read it.
Read articleOn May 19, the Department of Energy's Office of Critical Minerals and Energy Innovation announced 19 selections under FOA 3105 — two pilot-scale facilities for magnesium and rare-earth separation, and 17 technology development projects spanning lithium, cobalt, nickel, graphite, silicon, and manganese. Here is what the selection list tells researchers and small businesses about where DOE wants the supply chain in 18 months — and where the next solicitations will go.
Read article